Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Apitox

Other · developed by Apimeds

Phase 3 Most advanced trial (none active)

APUS Developer

1 Registered trials

What is Apitox?

Apitox is an investigational drug studied in Multiple Sclerosis.

At a glance

Drug type: Other
Therapy area: Neurology
Developer: Apimeds, Inc. (APUS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03710655	Phase 3	Multiple Sclerosis	Unknown	APUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Multiple Sclerosis

More from Apimeds

Honeybee venom Phase 2

Sources

ClinicalTrials.gov NCT03710655

Updated Oct 3, 2026. Something wrong or missing? Report it on the APUS page.

Follow APUS, the company behind Apitox

See APUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

APUS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z